Capital Movements on Borsa Istanbul: Record Free Issue from ONCSM, Strategic Allocation from BAYRK

As companies on Borsa Istanbul accelerate efforts to strengthen their capital structures, Oncosem Onkolojik Sistemler, a key player in the oncology sector, and Bayrak Ebt Taban, operating in the base industry, have signed critical decisions that place them at the center of investor attention. The decisions made by both companies represent a capital engineering nature that will deeply impact both their balance sheet structures and the market dynamics of their stocks.

ONCSM's 1,200% Free Capital Shock

Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.Ş. (ONCSM) decided to increase its capital at a record rate from internal resources, following a Board of Directors decision. The company will raise its current issued capital of 23.85 million TL to 310.05 million TL through a 1,200% free capital increase.

■The total capital increase amount will be 286.2 million TL.

■The source of funding will be other retained earnings, equity inflation adjustment differences, and issue premium accounts.

■The company obtained the right to exceed the current registered capital ceiling of 99 million TL once, within the framework of relevant regulations.

Strategic Transformation via Debt Offsetting at BAYRK

Bayrak Ebt Taban Sanayi ve Ticaret A.Ş. (BAYRK) drew attention with steps taken for debt restructuring and balance sheet optimization, deciding to make a capitalized capital increase by completely restricting the pre-emptive rights of existing shareholders. In return for a sales price of 132 million TL, the company will issue B group bearer shares in accordance with the Borsa Istanbul Wholesale Purchase and Sale Procedures.

■The shares to be issued will be allocated in offset of the 132 million TL cash and due receivables of Kurt Taban Ayakkabı Sanayi Ticaret A.Ş. from the company.

■The number of shares to be issued in the allocated sale and the nominal amount of the capital increase will become clear depending on the determined share sales price.

The 1,200% free issue in ONCSM creates a classic "node" point for the price to retest index moving averages (MA50/MA200). Deepening the liquidity of long positions before slipping below the Ichimoku cloud is key. BAYRK, by converting receivables into equity, optimizes financial leverage ratios; this could trigger a fundamental analysis-driven valuation correction in the stock.